奥赛康：子公司注射用德拉沙星葡甲胺获药品注册证书

Core Viewpoint - Aosaikang's subsidiary has received approval for the injection of Delafloxacin Mesylate, marking it as the only product of its kind approved for sale in China, addressing a gap in the domestic market [1] Group 1: Product Approval and Market Impact - The approved drug is indicated for the treatment of acute bacterial skin and skin structure infections as well as community-acquired bacterial pneumonia [1] - Delafloxacin is noted for its strong antibacterial activity, low resistance potential, and good safety profile [1] - The approval is expected to enhance the company's anti-infection product portfolio and positively impact its operations [1] Group 2: Market Potential - The sales revenue for quinolone antibiotics is projected to reach approximately 4.9 billion yuan in 2024, indicating significant market potential [1] - The introduction of this product will fill a void in the domestic market, suggesting a strategic advantage for the company [1] - However, the sales performance of the product remains uncertain [1]